Formulation: A solid
Formal Name: (3S)-N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide
Purity: ≥95%
Formula Markup: C18H21N3O5S2
Formula Weight: 423,5
Shelf life (days): 1460
CAS Number: 192329-42-3
Notes: Prinomastat is an inhibitor of matrix metalloproteinase-2 (MMP-2), MMP-3, MMP-9, MMP-13, and MMP-14 (IC50s = 0.05, 0.3, 0.26, 0.03, and 0.33 nM, respectively).{57531} It is selective for these MMPs over MMP-1 and MMP-7 (IC50s = 8.3 and 54 nM, respectively). Prinomastat (50 mg/kg) reduces tumor growth and inhibits the formation of lung metastases in a murine Lewis lung carcinoma model. It also reduces the incidence of kidney, but not brain, metastasis and tumor microvessel density in an NCI H460 lung cancer orthotopic mouse model when administered at a dose of 100 mg/kg.{57532} Prinomastat reduces bronchoalveolar lavage fluid (BALF) levels of TNF-α and pulmonary edema in a rat model of ventilator-induced lung injury.{57533}
English
Deutsch
